This MoCo biotech just raised another $20M to get its superbug-killing therapy through the clinic

Gaithersburg’s Adaptive Phage Therapeutics Inc. has raised another $20 million in funding, less than a year after securing nearly $41 million to advance its therapy for superbugs. The new funding brings the Series B total to $61 million, allowing the company to accelerate clinical trials for two programs: prosthetic joint infection and diabetic foot osteomyelitis, in which soft tissue infections can spread to the bone and require amputation.